Refining favorable-risk classification in pediatric RUNX1::RUNX1T1 acute myeloid leukemia

Risk stratification remains fundamental to the management of pediatric acute myeloid leukemia (pAML).1 It serves not only to estimate prognosis but also to guide treatment intensity, inform follow-up planning, and help clinicians balance disease control against treatment-related toxicity. Within this framework, pAML harboring the RUNX1::RUNX1T1 fusion has long been regarded as a favorable-risk subtype. At the cohort level, this classification is broadly justified. Yet it is not equally informative for every patient. Some children assigned to this category still relapse or experience poor survival outcomes, indicating that clinically meaningful heterogeneity persists within an apparently favorable subgroup.2 In this context, the study by Xun et al2 addresses this issue in a focused and clinically relevant manner. Rather than disputing the overall prognostic value of the RUNX1::RUNX1T1 fusion, the authors pose a narrower question: how can clinicians identify patients whose outcomes do not align with the expectations associated with favorable-risk disease? Their answer is a 2-factor model based on minimal residual disease after induction therapy and peripheral blood blast percentage at diagnosis.3 Using these routinely available variables, the model identified a subgroup with significantly inferior overall survival and event-free survival, reclassifying more than 30% of patients as high risk. Importantly, the model performed consistently across validation cohorts.4 One of the main strengths of this study is its practicality. In recent years, prognostic studies in leukemia have increasingly relied on transcriptomic profiling, genomic subtyping, and other high-dimensional approaches. These methods have deepened biological understanding and, in some settings, improved predictive precision. However, their integration into routine care remains uneven. Cost, technical requirements, turnaround time, and institutional variability continue to limit broad implementation. By contrast, the present model relies on parameters already used in standard clinical evaluation.5 Its value, therefore, lies not only in what it predicts but also in the fact that it can be applied without waiting for complex molecular workflows. Precision medicine is not defined solely by technological sophistication; it may also depend on a more rigorous use of information already at hand. The study also highlights a broader issue in leukemia classification. General risk stratification systems remain indispensable, but they are designed for large patient populations and may not always capture variation within biologically distinct subgroups. In RUNX1::RUNX1T1-positive pAML, the favorable-risk label has been clinically useful, yet it may also obscure a subset of patients whose disease behaves differently from what that label implies. The current analysis suggests that this is not a marginal problem. If a substantial proportion of patients classified as low risk can be separated into a group with clearly worse outcomes, subgroup-specific refinement becomes directly relevant to routine clinical decision-making. Another important feature of this study is that it moves beyond risk assignment alone. Among patients identified as high risk, KIT mutations, particularly exon 17 mutations, were associated with especially poor outcomes. In this setting, dasatinib treatment was associated with improved survival.6 These findings are noteworthy not only because they suggest a potential therapeutic option but also because they illustrate a larger point: the clinical significance of a molecular lesion may depend on the context in which it occurs. Mutations are often discussed as if they have fixed significance, yet their prognostic and therapeutic implications may become clearer when interpreted alongside disease burden and early treatment response. The authors also explored the subgroup of high-risk patients without KIT mutations. Their transcriptional and drug-sensitivity analyses revealed altered immune-related features, including CD200 upregulation and TLR3 downregulation, as well as increased predicted sensitivity to several small-molecule inhibitors.7,8 These observations remain exploratory and do not, by themselves, warrant immediate changes in practice. Nevertheless, they extend the significance of the model beyond prognosis. A useful stratification system should not only identify patients at risk; it should also help frame the next therapeutic questions worth pursuing. These findings should be interpreted with appropriate caution. Although the model was supported by retrospective analyses and performed well across validation cohorts, prospective evaluation is still necessary before it can guide treatment modifications in routine care.9 The same caution applies to the apparent benefit of dasatinib and to the candidate vulnerabilities proposed for KIT-wild-type high-risk disease. Currently, these results are better understood as clinically meaningful signals rather than definitive grounds for immediate changes in practice. Overall, this study makes a significant contribution to the management of RUNX1::RUNX1T1-positive pAML. It shows that favorable-risk classification, while useful, does not fully resolve the heterogeneity within this subgroup. It also illustrates a broader lesson in translational oncology: progress does not always come from adding more complexity; sometimes it arises from asking more precise clinical questions and applying routine variables with greater rigor.10 For this subgroup of pediatric AML, the challenge is no longer simply to recognize its generally favorable prognosis but to identify early and reliably those patients for whom that prognosis does not hold. In this sense, the present study represents a practical step toward more individualized care.